Cheilectomy yielded low revision, pain recurrence rates in patients with hallux rigidus
Click Here to Manage Email Alerts
Cheilectomy may be a reliable procedure for treatment of hallux rigidus, with low revision and pain recurrence rates among patients, according to study results.
Daniel J. Fuchs, MD, and colleagues administered a questionnaire about patient satisfaction with surgery, likelihood to undergo the same surgery again, pain recurrence after surgery, shoe wear limitations and ability to perform various activities to 165 patients who underwent cheilectomy for treatment of symptomatic hallux rigidus. Fuchs noted 18%, 70% and 12% of patients had Coughlin and Shurnas grades 1, 2 and 3, respectively.
“We found that 70% of patients had no pain at final follow-up, with 17% of patients having pain relief and then recurrence, and 13% never improved from surgery,” Fuchs said at a meeting.
Fuchs noted there was significant improvement in the VAS pain score from 64 to 11.
“Even in the cohort of patients with residual pain, they had improved VAS scores, which was statistically significant,” he said.
Most recurrence of pain occurred in first 2 years, according to Fuchs.
Postoperatively, nine patients reported an increase of pain and nine patients underwent revision surgery at an average of 3.6 years. Fuchs said 75% of patients reported they would undergo the same surgery again, and female gender and younger age were considered risk factors for recurrence of pain.
“In terms of patient’s ability to wear shoes postoperatively, 48% of women could wear a 1-inch or higher heel, 25% a flat dress shoe and 27% a comfortable shoe, whereas 84% of men could wear a dress shoe,” Fuchs said in his presentation. – by Casey Tingle
- Reference:
- Sidon E, et al. Foot Ankle Int. 2019;doi:10.1177/1071100719859236.
- For more information:
- Daniel J. Fuchs, MD, can be reached at Rothman Orthopaedic Institute, 2400 Mary-land Road, Suite 20, Willow Grove, PA 19090; email: alex.hammond@rothmanortho.com.
Disclosures: Fuchs reports no relevant financial disclosures.